A Top UK Midcap Performer’s US Plans Help it Evade Tariff Glare

A provider of cell and gene therapy services is among the best performers in Britain’s midcap stock gauge this quarter, helped by a growing US manufacturing presence that has kept it away from the glare of President Donald Trump’s tariffs regime....

Redirecting to full article...